or Try an Advanced Search...

    Technical Analysis for RENB - Renovaro Biosciences Inc.

    Grade Last Price % Change Price Change
    F 0.86 -9.22% -0.09
    RENB closed down 8.91 percent on Wednesday, May 15, 2024, on 67 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical RENB trend table...
    Date Alert Name Type % Chg
    Wide Bands Range Expansion -9.22%
    Gapped Up Strength -9.22%
    Oversold Stochastic Weakness -9.22%
    Wide Bands Range Expansion -17.31%
    Oversold Stochastic Weakness -17.31%
    Earnings Movers Other -25.86%
    Outside Day Range Expansion -25.86%
    Wide Bands Range Expansion -25.86%
    Gapped Up Strength -25.86%
    Oversold Stochastic Weakness -25.86%
    Older End-of-Day Signals for RENB ...

       Recent Intraday Alerts

    Alert Time
    Down 10% about 2 hours ago
    Outside Day about 2 hours ago
    Down 5% about 2 hours ago
    Fell Below Previous Day's Low about 2 hours ago
    Down 3% about 3 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    RENB Chart by TradingView
    Basic chart:

    Profile

    Renovaro Biosciences Inc. Description

    Enochian Biosciences Inc., a pre-clinical stage biotechnology company, focuses on development of human therapeutics for infectious diseases and cancers. The company's lead candidate include ENOB-HV-01 for autologous HIV curative treatment. Its pipeline development products consist of ENOB-HV-11, a preventive HIV vaccine; and ENOB-HV-12, a therapeutic HIV vaccine. The company's pipeline development products also include ENOB-DB-01, a therapeutic cancer vaccine for the long term maintenance and prevention of relapse for the treatment of stage III and IV colon cancer patients; ENOB-DC-11 Innovative DC vaccine for multiple solid tumors; and ENOB-DC-21 for intratumoral injection. The company has strategic partnerships with The Scripps Institute and Fred Hutchinson Cancer Center. Enochian BioSciences was incorporated in 2017 and is based in Los Angeles, California.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Cancer Solid Tumors Infectious Diseases Vaccines HIV Cancer Vaccine

    Is RENB a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 30 Transforming Cancer Detection: RenovaroCube Introduces Flamingo, a novel AI model based on Fragmentomics
    Apr 24 RenovaroCube to acquire 100% ownership of Cyclomics
    Apr 24 RenovaroCube to Acquire 100% Ownership of Cyclomics, Reinforcing Cutting-Edge Cancer Diagnostics Partnership
    Apr 18 Renovaro Inc. Proudly Announces the Appointment Of Professor Dr. Geert Kazemier as the Chairman of its Scientific Advisory Board, A Move That Heralds a New Era of Innovation and Progress in its Mission to Reshape Cancer Screening, Diagnosis, and Patien...
    Feb 14 Renovaro Biosciences soars after responding to Hindenburg short call
    Feb 14 Statement of Renovaro Inc
    Feb 13 Renovaro Biosciences Faces Turmoil After Hindenburg Report Accusing Questionable Merger And Governance, Stock Crashes
    Feb 13 Renovaro Biosciences plunges amid Hindenburg Research short call
    Feb 13 Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace
    Feb 13 AI Pioneer GEDi Cube and Biotech Innovator Renovaro Biosciences Combine Forces to Accelerate Personalized Medicine
    See more RENB news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 5.25
    52 Week Low 0.3928
    Average Volume 353,001
    200-Day Moving Average 2.98
    50-Day Moving Average 2.32
    20-Day Moving Average 1.57
    10-Day Moving Average 1.29
    Average True Range 0.24
    RSI (14) 18.70
    ADX 36.91
    +DI 8.43
    -DI 31.48
    Chandelier Exit (Long, 3 ATRs) 1.99
    Chandelier Exit (Short, 3 ATRs) 1.61
    Upper Bollinger Bands 2.32
    Lower Bollinger Band 0.82
    Percent B (%b) 0.09
    BandWidth 95.92
    MACD Line -0.37
    MACD Signal Line -0.34
    MACD Histogram -0.027
    Fundamentals Value
    Market Cap 63.68 Million
    Num Shares 67.2 Million
    EPS -0.71
    Price-to-Earnings (P/E) Ratio -1.33
    Price-to-Sales 0.00
    Price-to-Book 5.19
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.29
    Resistance 3 (R3) 1.31 1.22 1.23
    Resistance 2 (R2) 1.22 1.13 1.21 1.22
    Resistance 1 (R1) 1.08 1.08 1.04 1.06 1.20
    Pivot Point 0.99 0.99 0.97 0.98 0.99
    Support 1 (S1) 0.85 0.90 0.81 0.83 0.70
    Support 2 (S2) 0.76 0.85 0.75 0.68
    Support 3 (S3) 0.62 0.76 0.66
    Support 4 (S4) 0.60